{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:57:29Z","timestamp":1781672249635,"version":"3.54.5"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Autosomal dominant hypocalcemia type 1 (ADH1) is a rare genetic disorder caused by gain-of-function variants in the\n                      <jats:italic>CASR<\/jats:italic>\n                      gene, leading to suppressed parathyroid hormone (PTH) secretion, hypocalcemia, hyperphosphatemia, hypomagnesemia and hypercalciuria. Evidence on the use of long-acting PTH analogs in pediatric ADH1 remains scarce. This report describes a boy with a\n                      <jats:italic>de novo<\/jats:italic>\n                      heterozygous activating\n                      <jats:italic>CASR<\/jats:italic>\n                      variant and highlights the therapeutic response to palopegteriparatide.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 16-year-old boy presented with hypocalcemia, recurrent tetany, seizures, hypercalciuria, nephrocalcinosis, basal ganglia calcifications, and early-onset cataracts. He had been diagnosed with congenital hypoparathyroidism at 6 weeks of age. A heterozygous\n                      <jats:italic>CASR<\/jats:italic>\n                      variant [c.2504C&amp;gt;A; p.(Ala835Asp)] causing ADH1 was identified. Despite long-term therapy with alfacalcidol, calcium, and magnesium supplements, symptoms persisted and biochemical control remained poor, with pronounced hyperphosphatemia and an elevated calcium\u2013phosphate product.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention and outcomes<\/jats:title>\n                    <jats:p>Owing to inadequate disease control on Standard-of-Care, off-label treatment with palopegteriparatide was initiated. The dose was adjusted to alleviate neuromuscular symptoms while reducing calcium-phosphate product. The patient subsequently reported complete resolution of tetany with improved biochemical stability, reduced phosphate levels, and a lower calcium\u2013phosphate product. At the final maintenance dose, both alfacalcidol and calcium supplementation were successfully discontinued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates that palopegteriparatide may be a valuable therapeutic option in pediatric patients with ADH1 when conventional therapy fails to provide adequate control and while targeted therapies directed at the mutated CASR are not yet available. Carefully titrated PTH-based therapy can improve symptoms and mineral homeostasis, highlighting the need for further studies on its long-term safety and efficacy in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1837966","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:46:47Z","timestamp":1781671607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Palopegteriparatide as a novel therapeutic option in pediatric autosomal dominant hypocalcemia type 1"],"prefix":"10.3389","volume":"17","author":[{"given":"Arkadiusz","family":"Zygmunt","sequence":"first","affiliation":[{"name":"Department of Developmental Age and Adult Endocrinology, Medical University of Lodz","place":["Lodz, Poland"]},{"name":"Department of Endocrinology and Metabolic Diseases, Polish Mother\u2019s Memorial Hospital \u2013 Research Institute","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fedorczak","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases, Polish Mother\u2019s Memorial Hospital \u2013 Research Institute","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Krotowski","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases, Polish Mother\u2019s Memorial Hospital \u2013 Research Institute","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"\u0141upi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Developmental Age and Adult Endocrinology, Medical University of Lodz","place":["Lodz, Poland"]},{"name":"Department of Endocrinology and Metabolic Diseases, Polish Mother\u2019s Memorial Hospital \u2013 Research Institute","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Sa\u0142aci\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Genetics, Polish Mother\u2019s Memorial Hospital \u2013 Research Institute","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Gach","sequence":"additional","affiliation":[{"name":"Department of Genetics, Polish Mother\u2019s Memorial Hospital \u2013 Research Institute","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mannstadt","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital and Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Stawerska","sequence":"additional","affiliation":[{"name":"Department of Developmental Age and Adult Endocrinology, Medical University of Lodz","place":["Lodz, Poland"]},{"name":"Department of Endocrinology and Metabolic Diseases, Polish Mother\u2019s Memorial Hospital \u2013 Research Institute","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4659","article-title":"Autosomal dominant hypocalcemia type 1: A systematic review","volume":"37","author":"Roszko","year":"2022","journal-title":"J Bone Miner. Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02496-y","article-title":"Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations","volume":"48","author":"De Coster","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115178","article-title":"Amino alcohol- (NPS-2143) and quinazolinone-derived calcilytics (ATF936 and AXT914) differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome type 5 and autosomal dominant hypocalcemia","volume":"9","author":"Letz","year":"2014","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2007.00096.x","article-title":"Structure and function of the human calcium-sensing receptor: Insights from natural and engineered mutations and allosteric modulators","volume":"11","author":"Hu","year":"2007","journal-title":"J Cell Mol Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20067","article-title":"CASRdb: Calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia","volume":"24","author":"Pidasheva","year":"2004","journal-title":"Hum Mutat"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.104041","article-title":"Calcium-sensing receptor: Role in health and disease","volume":"16","author":"Thakker","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.3.8280","article-title":"Identification and functional characterization of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia","volume":"87","author":"D'Souza-Li","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","unstructured":"The CASR gene homepage - Global Variome shared LOVD"},{"key":"B9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/clinem\/dgae769","article-title":"CASRdb: A publicly accessible comprehensive database for disease-associated calcium-sensing receptor variants","volume":"110","author":"Charoenngam","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2020.04.006","article-title":"Familial hypocalciuric hypercalcemia type 1 and autosomal-dominant hypocalcemia type 1: Prevalence in a large healthcare population","volume":"106","author":"Dershem","year":"2020","journal-title":"Am J Hum Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2025.06.013","article-title":"A calcium-sensing receptor allelic series and underdiagnosis of genetically driven hypocalcemia","volume":"112","author":"Chang","year":"2025","journal-title":"Am J Hum Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00608.2009","article-title":"Physiology and pathophysiology of the calcium-sensing receptor in the kidney","volume":"298","author":"Riccardi","year":"2010","journal-title":"Am J Physiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Mineral. Res.: Off J Am Soc For. Bone Mineral. Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjag034","article-title":"Autosomal dominant hypocalcemia type 1: Status quo of tailored management and future perspectives","author":"Harada","year":"2026","journal-title":"J Bone Mineral. Res.: Off J Am Soc For. Bone Mineral. Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/JME-16-0124","article-title":"Disorders of the calcium-sensing receptor and partner proteins: Insights into the molecular basis of calcium homeostasis","volume":"57","author":"Hannan","year":"2016","journal-title":"J Mol Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-017-0570-z","article-title":"Diseases associated with calcium-sensing receptor","volume":"12","author":"Vahe","year":"2017","journal-title":"Orphanet. J Rare. Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2018.07.007","article-title":"Genetic disorders of parathyroid development and function","volume":"47","author":"Gordon","year":"2018","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa113","article-title":"Hypoparathyroidism","volume":"105","author":"Bilezikian","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1800213","article-title":"Hypoparathyroidism","volume":"380","author":"Gafni","year":"2019","journal-title":"N. Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2016.00458","article-title":"Autosomal dominant hypocalcemia (hypoparathyroidism) types 1 and 2","volume":"7","author":"Roszko","year":"2016","journal-title":"Front Physiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.108404","article-title":"Characterization of quinazolinone calcilytic therapy for autosomal dominant hypocalcemia type 1 (ADH1)","volume":"301","author":"Hannan","year":"2025","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.62347\/QGTS5711","article-title":"The calcium-sensing receptor: A comprehensive review on its role in calcium homeostasis and therapeutic implications","volume":"17","author":"Yuan","year":"2025","journal-title":"Am J Trans Res"},{"key":"B23","unstructured":"CALIBRATE: A phase 3, randomized, open-label study evaluating the efficacy and safety of encaleret compared to standard of care in participants with autosomal dominant hypocalcemia type 1 (ADH1)\n          \n          \n          \n          2025"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2302708","article-title":"Efficacy and safety of encaleret in autosomal dominant hypocalcemia type 1","volume":"389","author":"Gafni","year":"2023","journal-title":"N. Engl J Med"},{"key":"B25","volume-title":"United kingdom\u2019s MHRA approves YORVIPATH\u00ae (Palopegteriparatide) in great britain for the treatment of adults with chronic hypoparathyroidism","year":""},{"key":"B26","unstructured":"YORVIPATH Palopegteriparatide 294 Micrograms \/ 0.98 mL Solution for Injection in Multidose Pre-Filled Pen, (443871) | Therapeutic goods administration (TGA)\n          \n          \n          Therapeutic Goods Administration (TGA\n          \n          2025"},{"key":"B27","article-title":"Yorvipath","year":"2023"},{"key":"B28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Mineral. Res.: Off J Am Soc For. Bone Mineral. Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1837966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:46:56Z","timestamp":1781671616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1837966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":28,"alternative-id":["10.3389\/fendo.2026.1837966"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1837966","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1837966"}}